GlassScriptPhysician profile
Gordon M Moss
NPI 1639154925
$4,808.49
in general payments reported to CMS, 2019-2025
30 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $124 · 2021: $625 · 2022: $768 · 2023: $679 · 2024: $619 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $913.18 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $566.23 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $444.19 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $402.64 | 2021-2025 | |
| Pfizer INC. | $387.35 | 2019-2023 | |
| Glaxosmithkline, LLC. | $311.69 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.34 | 2019-2025 | Jardiance, Jascayd |
| Novartis Pharmaceuticals Corporation | $290.77 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.96 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $164.34 | 2019-2021 | |
| Dexcom, INC. | $136.89 | 2021-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $112.17 | 2021-2025 | Nexletol |
| Abbott Laboratories | $95.80 | 2021-2023 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $71.71 | 2019-2021 | |
| Exact Sciences Corporation | $70.26 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $43.13 | 2022 | |
| Astellas Pharma US INC | $41.93 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $36.60 | 2024 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $33.85 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.14 | 2019 | |
| Alnylam Pharmaceuticals INC. | $32.97 | 2024 | Onpattro |
| Seqirus USA INC | $29.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.18 | 2019-2022 | |
| Eisai INC. | $20.08 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.15 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2021 | |
| Inari Medical, INC. | $14.06 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bausch Health US, LLC | $13.76 | 2019 | |
| Sanofi Pasteur INC. | $12.54 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.